DCC and neoplasm: Finally, the review discusses the kinetics of DCC proliferation, as inferred through serum tumor marker lead time (LT), and presents the mechanistic rationale underlying a protocol designed to eradicate DCCs in patients with solid tumors at high risk of relapse.